NXGL.NASDAQNexgel, INC
10-Q: NexGel, Inc. Reports Strong Revenue Growth in Q1 2025, Despite Ongoing Losses
Sentiment:
Quarterly Report
NexGel, Inc. saw a significant increase in revenue for the first quarter of 2025, driven by growth in contract manufacturing and branded products, but continues to operate at a loss.
Capital raiseThe Company continues to evaluate strategic initiatives (e.g., acquisitions) and additional capital raises through debt or equity may be necessary to achieve these objectives.Management may consider various options to raise capital to fund potential acquisitions through equity or debt offerings.
Worse than expectedDespite significant revenue growth, the company continues to operate at a loss and faces substantial doubt about its ability to continue as a going concern.
Summary
- NexGel, Inc. reported its financial results for the quarter ended March 31, 2025.
- The company's net revenues increased significantly to $2.806 million, compared to $1.266 million in the same period last year, representing a 121.6% increase.
- This growth was primarily driven by increased sales in both contract manufacturing and branded products.
- Despite the revenue growth, the company reported a net loss attributable to NexGel stockholders of $712 thousand, or $0.09 per share, compared to a net loss of $853 thousand, or $0.14 per share, for the same period in 2024.
- The company's gross profit increased to $1.188 million, compared to $160 thousand in the prior year.
- Operating expenses increased to $1.965 million, compared to $1.031 million in the prior year.
- The company is exploring new product channel sales and focusing on developing a sales pipeline to improve financial stability.
- NexGel is also evaluating strategic initiatives and additional capital raises to achieve its objectives.
- The company acknowledges that it expects to continue incurring losses in the near term.
- There is substantial doubt about the company's ability to continue as a going concern.
Sentiment
Score: 4
Explanation: The document presents a mixed picture. While revenue growth is strong, the continued losses, going concern uncertainty, and internal control weaknesses raise significant concerns. The sentiment is therefore cautiously negative.
Positives
- Significant revenue growth of 121.6% indicates increasing market traction.
- Gross profit improvement suggests better cost management or higher-margin products.
- Net loss decreased compared to the same period last year, indicating progress towards profitability.
- The company is actively exploring new product channels and strategic initiatives to improve financial stability.
Negatives
- The company continues to operate at a net loss.
- Operating expenses increased significantly, offsetting some of the revenue gains.
- There is substantial doubt about the company's ability to continue as a going concern.
- Material weaknesses in internal control over financial reporting were identified.
Risks
- The company's ability to continue as a going concern is uncertain.
- The company may not be able to raise sufficient capital to execute its business plan.
- The company faces risks related to compliance with manufacturing practices, loss of key executives, and adverse economic conditions.
- The company is involved in a legal proceeding with Kiss Nail Products, which could have a material adverse effect on its business.
- Material weaknesses in internal control over financial reporting could lead to errors in financial reporting.
Future Outlook
The company expects to continue incurring losses for the near-term future and is exploring new product channel sales and strategic initiatives to improve financial stability. Additional capital raises through debt or equity may be necessary to achieve these objectives.
Management Comments
- Management is exploring new product channel sales in adjacent industries, such as cosmetics, athletic products, and proprietary medical devices.
- The Company has increased focus on sales and developing a sales pipeline for potential customers.
- We intend to maintain and attempt to grow our existing contract manufacturing business.
- We also plan to continue building and developing our catalogue of consumer products for sale to branding partners and to use our in-house capabilities to create and test market additional branded products.
- Furthermore, the Company plans to develop its own proprietary medical devices and explore drug delivery programs for its technology.
- Additionally, the Company continues to evaluate strategic initiatives (e.g., acquisitions), and additional capital raises through debt or equity may be necessary to achieve these objectives.
- Our ability to continue to operate as a going concern in the long-term is dependent upon our ability to manage and grow our current products and to ultimately achieve profitable operations.
Industry Context
The company operates in the hydrogel manufacturing industry, serving the wound care, medical diagnostics, transdermal drug delivery, and cosmetics markets. The company's strategy includes expanding its branded consumer product lines through acquisitions and joint ventures, as well as developing its own proprietary medical devices.
Comparison to Industry Standards
- It is difficult to compare NexGel's results directly to industry standards without specific competitor data.
- However, the company's revenue growth of 121.6% suggests it is outperforming some competitors in its niche markets.
- The company's continued losses and going concern uncertainty are concerning and indicate it is underperforming compared to more established and profitable companies in the broader healthcare and consumer products industries.
- Companies like Integra LifeSciences (IART) in the wound care market and Johnson & Johnson (JNJ) in the consumer health market serve as benchmarks for profitability and stability, which NexGel is currently not meeting.
Legal Proceedings
- On April 9, 2025, the company filed a Complaint for Declaratory Judgment against Kiss Nail Products, Inc. regarding a patent dispute related to eyelash extension products.
Related Party Transactions
- The company had outstanding balances due to C.G. Laboratories, Inc. and Russell Crum, the CEO of CG Labs, for contract manufacturing, packaging, and other services.
Stakeholder Impact
- Shareholders face uncertainty due to the company's going concern status and potential for further losses.
- Employees' job security is uncertain due to the company's financial instability.
- Customers may be concerned about the company's ability to fulfill orders and maintain product quality.
- Suppliers may face increased credit risk due to the company's financial challenges.
- Creditors face increased risk of default due to the company's financial instability.
Next Steps
- The company intends to submit the 780,000 share increase under the 2019 Plan for stockholder approval as part of the 2025 Proxy Statement.
- The company expects to complete remediation efforts for material weaknesses in internal control over financial reporting by June 30, 2025 or, at the latest, by September 30, 2025.
Key Dates
| Date | Description |
|---|---|
| 2019-09-10 | Date of warrant issuance |
| 2019-11-06 | Date of warrant issuance |
| 2020-03-18 | Date of warrant issuance |
| 2020-05-27 | Date of Economic Injury Disaster Loan |
| 2020-05-28 | Date of Economic Injury Disaster Loan |
| 2020-12-24 | Date of warrant issuance |
| 2021-02-03 | Date of warrant issuance |
| 2021-03-11 | Date of warrant issuance |
| 2021-05-03 | Board approved an increase of the number of authorized shares of common stock reserved under the 2019 Plan |
| 2021-05-31 | Date of warrant issuance |
| 2021-09-02 | Date of warrant issuance |
| 2023-01-06 | Company acquired a 50 % interest in a newly formed joint venture (Enigma JV) |
| 2023-03-01 | Company acquired a 50 % interest in a newly formed joint venture (CGN JV) |
| 2023-12-01 | Company purchased all assets related to the Kenkoderm Sellers skincare line |
| 2024-01-01 | Effective date of restricted stock award to Adam Levy |
| 2024-02-11 | Promissory note agreement for certain leasehold improvements |
| 2024-02-15 | Company entered into subscription agreements with investors and certain members of its board of directors and management for the sale by the Company of an aggregate of 242,891 units at a price to the public of $ 4.22 per unit |
| 2024-03-13 | Promissory note has a term of five years beginning on March 13, 2024 |
| 2024-05-15 | Company purchased the Silly George assets |
| 2024-12-31 | The Enigma JV was dissolved on December 23, 2024 |
| 2024-12-31 | Board approved an additional 780,000 shares of common stock to be reserved under the 2019 Plan |
| 2025-01-01 | Effective date of fully vested restricted stock awards of 2,500 shares of the Company's common stock to two board members |
| 2025-01-02 | Company granted options to purchase up to 150,000 shares of the Company's common stock at a per share exercise price of $ 3.83 to Adam Levy |
| 2025-01-02 | Company granted options to purchase up to 100,000 shares of the Company's common stock at a per share exercise price of $ 3.83 to Joe McGuire |
| 2025-01-02 | Company granted an aggregated restricted stock award of 4,082 fully vested shares of the Company's common stock to Joseph McGuire for reimbursed expenses in the prior year |
| 2025-02-11 | Promissory note agreement for certain leasehold improvements |
| 2025-03-31 | End of the quarterly period |
| 2025-04-09 | Company filed a Complaint for Declaratory Judgment against Kiss Nail Products, Inc. |
| 2025-05-13 | As of May 13, 2025 the registrant had 7,654,537 shares of common stock outstanding |
| 2025-06-30 | Expected completion date for remediation efforts of material weaknesses in internal control over financial reporting |
| 2025-09-30 | Latest expected completion date for remediation efforts of material weaknesses in internal control over financial reporting |
Keywords
NexGel, financial results, hydrogels, contract manufacturing, branded consumer products, revenue growth, net loss, going concern, internal control, Silly George, Kenkoderm
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.